significant new advance to prevent serious respiratory syncytial virus (RSV) infections in young children
There's a significant new advance to prevent serious respiratory syncytial virus (RSV) infections in young children.
It's called Synagis (palivizumab)...for preemies and young children with lung disease who are at risk for pulmonary RSV infections.
Synagis is a monoclonal antibody. It binds to a protein on the surface of the virus to prevent it from infecting cells.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote